Overview

A Randomized, Double Blind Study Evaluating Paclitaxel With and Without RAD001 in Patients With Gastric Carcinoma After Prior Chemotherapy

Status:
Completed

Trial end date:
2019-10-01

Target enrollment:

Participant gender:

Summary

Adult patients with gastric carcinoma which has progressed after initial treatment with a fluoropyrimidines-containing regimen will be treated with paclitaxel plus RAD001 or plus placebo. The hypothesis is that patients with RAD001 have significantly prolonged overall survival compared to patients who are treated with paclitaxel alone.

Phase:

Phase 3

Details

Lead Sponsor:

Krankenhaus Nordwest

Treatments:

Albumin-Bound Paclitaxel
Everolimus
Paclitaxel
Sirolimus